Research Article

Safety and Efficacy of Long-Term Zoledronic Acid in Advanced Breast Cancer with Bone Metastasis in South China

Figure 1

(a) The cumulative incidence of all 426 SREs that occurred after the initiation of ZA in the 241 breast cancer patients with bone metastasis; 70.2% of SREs occurred in the first 24 months. (b) The cumulative incidence of 178 and 248 SREs in group A and group B, respectively. In the first 24 months, 93.8% and 53.2% of SREs occurred in group A (ZA 6–24 months) and group B (ZA > 24 months), respectively.